Long-term toxicity of bevacizumab therapy in neurofibromatosis 2 patients-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Long-term toxicity of bevacizumab therapy in neurofibromatosis 2 patients

Published:2014-04-08 Issue:6 Volume:73 Page:1197-1204
ISSN:0344-5704
Container-title:Cancer Chemotherapy and Pharmacology
language:en
Short-container-title:Cancer Chemother Pharmacol

Author:

Slusarz Katherine M.,Merker Vanessa L.,Muzikansky Alona,Francis Sanjeev A.,Plotkin Scott R.

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s00280-014-2456-2.pdf

Reference24 articles.

1. Evans DG, Sainio M, Baser ME (2000) Neurofibromatosis type 2. J Med Genet 37:897–904

2. Plotkin SR, Stemmer-Rachamimov AO, Barker FG 2nd, Halpin C, Padera TP, Tyrrell A, Sorensen AG, Jain RK, di Tomaso E (2009) Hearing improvement after bevacizumab in patients with neurofibromatosis type 2. N Engl J Med 361:358–367

3. Mautner VF, Nguyen R, Kutta H, Fuensterer C, Bokemeyer C, Hagel C, Friedrich RE, Panse J (2010) Bevacizumab induces regression of vestibular schwannomas in patients with neurofibromatosis type 2. Neuro Oncol 12:14–18

4. Eminowicz GK, Raman R, Conibear J, Plowman PN (2011) Bevacizumab treatment for vestibular schwannomas in neurofibromatosis type two: report of two cases, including responses after prior gamma knife and vascular endothelial growth factor inhibition therapy. J Laryngol Otol 126:79–82

5. Plotkin SR, Merker VL, Halpin C, Jennings D, McKenna MJ, Harris GJ, Barker FG (2012) Bevacizumab for progressive vestibular schwannoma in neurofibromatosis type 2: a retrospective review of 31 patients. Otol Neurotol 33:1046–1052

Cited by 64 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Concerning Case of Severe Gastritis With Gastrointestinal Protein Loss;Gastroenterology;2024-08

2. Synergistic effect of PAK and Hippo pathway inhibitor combination in NF2-deficient Schwannoma;PLOS ONE;2024-07-31

3. Phase I/II Study of a Vascular Endothelial Growth Factor Receptor Vaccine in Patients With NF2-Related Schwannomatosis;Journal of Clinical Oncology;2024-07-20

4. Brigatinib in NF2 -Related Schwannomatosis with Progressive Tumors;New England Journal of Medicine;2024-06-27

5. Gene Therapy for Neurofibromatosis Type 2-Related Schwannomatosis: Recent Progress, Challenges, and Future Directions;Oncology and Therapy;2024-05-17

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3